Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5678619 | 0.85 | HPGD (0.57) | NPC1RAB9AKMT2AMEN1HPGD | |
| SCHEMBL15340453 | 0.84 | HCRTR1 (0.51) | NPC1RAB9AHCRTR1KMT2AMEN1 | |
| SCHEMBL12608929 | 0.76 | ALDH1A1 (0.54) | NPC1RAB9AHCRTR1KMT2AMEN1 | |
| SCHEMBL8431592 | 0.74 | KMT2A (0.68) | NPC1RAB9AKMT2AMEN1ESR1 | |
| SCHEMBL15340454 | 0.74 | NAAA (0.59) | NPC1KMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL30569764 | 0.74 | KMT2A (0.54) | KMT2APKMHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL29067146 | 0.74 | KMT2A (0.54) | KMT2APKMHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL15344057 | 0.74 | HCRTR1 (0.52) | HCRTR1KMT2AMEN1ESR1HPGD | |
| SCHEMBL10457215 | 0.73 | KMT2A (0.66) | NPC1RAB9AKMT2AMEN1ESR1 | |
| SCHEMBL29067151 | 0.73 | TSHR (0.50) | HCRTR1PKMHPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281520-A1 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281520-A1 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders | HSD17B14, SORD, GPX4 | NPC1 2779/4885RAB9A 4360/4885HCRTR1 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.